Tumor accumulation of poly(ethylene glycol) with different molecular weights after intravenous injection
Open Access
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 4 (1), 23-31
- https://doi.org/10.3109/10717549709033184
Abstract
Body distribution of poly(ethylene glycol) (PEG) with different molecular weights (MWs) was investigated after intravenous injection into mice with a tumor mass of their back subcutis and footpad to evaluate the effect of PEG molecular weight on the tumor accumulation. PEG did not exhibit specific affinity for any organs and PEG with higher MW tended to remain in the blood circulation of tumor-bearing mice longer than PEG with lower MW, similarly to normal mice. PEG accumulated at the tumor tissue to a significantly higher extent than at the normal tissue, irrespective of the molecular weight and the tumor loading site. Such high tumor accumulation of PEG increased with an increase in the size of the tumor mass, leveling off at a certain size. This size dependence was in accord with that of the vasculature volume in the tumor tissue. Because PEG extravasates to the interstitial space of the tumor, the tumor accumulation seems to be governed mainly by the level of hyperpermeable vasculature. The PEG molecules accumulated at the tumor tissue were retained longer than those at the normal tissue. The tumor accumulation of PEG became maximal at MW around 200,000. A pharmacokinetic study demonstrated that the accumulation rate of PEG at the tumor tissue was higher than that at the normal tissue and decreased with increasing molecular weight. On the other hand, the higher the molecular weight of PEG, the longer the retention time in the blood circulation. It is likely that the balance between these two factors, the accumulation rate of PEG and the blood retention, results in maximal accumulation of PEG with a medium molecular weight.Keywords
This publication has 18 references indexed in Scilit:
- Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1992
- Biliary excretion of mitomycin C dextran conjugates in relation to physicochemical characteristics of carrier dextran.Journal of Pharmacobio-Dynamics, 1990
- Clearance of charged and uncharged dextrans from normal and injured lungsJournal of Applied Physiology, 1990
- Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.Proceedings of the National Academy of Sciences, 1988
- Delivery of glutathione, as a dextran conjugate, into the liverInternational Journal of Pharmaceutics, 1988
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- Differential macromolecular leakage from the vasculature of tumorsCancer, 1986
- A new procedure for the synthesis of polyethylene glycol-protein adducts; Effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α2-macroglobulinAnalytical Biochemistry, 1983
- Modification of E. coli L-asparaginase with polyethylene glycol: Disappearance of binding ability to anti-asparaginase serumBiochemical and Biophysical Research Communications, 1978
- THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITYBiochemical Journal, 1963